Willem J. Lammers

Willem J. Lammers

Auto-generated profile, based on publicly available information

Willem J. Lammers

Department of Gastroenterology and Hepatology Erasmus University Medical Center Rotterdam The Netherlands

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2014 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
WLWillem J Lammers
Willem J Lammers
HBHenk R Van Buuren
Henk R Van Buuren
GHGideon M Hirschfield
Gideon M Hirschfield
HJHarry L A Janssen
Harry L A Janssen
PIPietro Invernizzi
Pietro Invernizzi
GGGlobal PBC Study Group
Global PBC Study Group

1 December 2015 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
WLWillem J. Lammers
Willem J. Lammers
GHGideon M. Hirschfield
Gideon M. Hirschfield
CCChristophe Corpechot
Christophe Corpechot
FNFrederik Nevens
Frederik Nevens
KLKeith D. Lindor
Keith D. Lindor
HBHenk R. van Buuren
Henk R. van Buuren

1 August 2019 in Journal of Hepatology
Verified
Journal Article
Closed access
MHMaren H. Harms
Maren H. Harms
HBHenk R. van Buuren
Henk R. van Buuren
CCChristophe Corpechot
Christophe Corpechot
DTDouglas Thorburn
Douglas Thorburn
HJHarry L.A. Janssen
Harry L.A. Janssen
Adriaan J. van der MeerAdriaan J. van der Meer
Adriaan J. van der Meer

6 January 2015 in Gut
Verified
Journal Article
Closed access
PDF file
PTPalak J Trivedi
Palak J Trivedi
WLWillem J Lammers
Willem J Lammers
HBHenk R van Buuren
Henk R van Buuren
APAlbert Parés
Albert Parés
AFAnnarosa Floreani
Annarosa Floreani
GHGideon M Hirschfield
Gideon M Hirschfield
Objective Hepatocellular carcinoma (HCC) is an infrequent yet critical event in primary biliary cirrhosis (PBC); however, predictive tools remain ill-defined. Our objective was to identify candidate risk factors for HCC development in patients with PBC. Design Risk factor analysis was performed in over 15 centres from North America and Europe spanning >40 years observation period using Cox proportional hazards assumptions, logistic regression, and Kaplan-Meier estimates. Results Of 4565 patients with PBC 123 developed HCC, yielding an incidence rate (IR) of 3.4 cases/1000 patient-years. HCC was significantly more common in men (p<0.0001), and on univariate analysis factors at PBC diagnosis associated with future HCC development were male sex (unadjusted HR 2.91, p<0.0001), elevated serum aspartate transaminase (HR 1.24, p<0.0001), advanced disease (HR 2.72, p=0.022), thrombocytopenia (HR 1.65, p<0.0001), and hepatic decompensation (HR 9.89, p<0.0001). As such, non-treatment with ursodeoxycholic acid itself was not associated with cancer development; however, 12-month stratification by biochemical non-response (Paris-I criteria) associated significantly with future risk of HCC (HR 4.52, p<0.0001; IR 6.6 vs 1.4, p<0.0001). Non-response predicted future risk in patients with early stage disease (IR 4.7 vs 1.2, p=0.005), advanced disease (HR 2.79, p=0.02; IR 11.2 vs 4.4, p=0.033), and when restricting the analysis to only male patients (HR 4.44, p<0.001; IR 18.2 vs 5.4, p<0.001). On multivariable analysis biochemical non-response remained the most significant factor predictive of future HCC risk (adjusted HR 3.44, p<0.0001). Conclusions This uniquely powered, internationally representative cohort robustly demonstrates that 12-month biochemical non-response is associated with increased future risk of developing HCC in PBC. Such risk stratification is relevant to patient care and development of new therapies.

1 February 2018 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
PDF file
MHMaren H Harms
Maren H Harms
WLWillem J Lammers
Willem J Lammers
DTDouglas Thorburn
Douglas Thorburn
CCChristophe Corpechot
Christophe Corpechot
PIPietro Invernizzi
Pietro Invernizzi
HBHenk R van Buuren
Henk R van Buuren
In this era of near universal ursodeoxycholic acid (UDCA) treatment for primary biliary cholangitis (PBC), progression to cirrhosis still occurs in an important proportion of patients. The aim of this study was to describe the incidence of cirrhosis-associated complications in patients with PBC and assess risk factors and impact on survival. Cohorts of UDCA-treated patients from 16 European and North-American liver centers were included. We used Cox proportional hazards assumptions and Kaplan–Meier estimates. During 8.1 years’ median follow-up, 278 of 3,224 patients developed ascites, variceal bleeding, and/or encephalopathy (incidence rate of 9.7 cases/1,000 patient years). The overall cumulative incidence was 9.1% after 10 years of follow-up, but decreased over time to 5.8% after the year 2000. Earlier calendar year of diagnosis (P<0.001), high aspartate aminotransferase to platelets ratio index (APRI; P<0.001) and biochemical non-response (P0.54 after 12 months of UDCA had a 10-year complication rate of 37.4%, as compared to 3.2% in biochemical responders with an APRI ≤0.54. The 10-year transplantation-free survival after a complication was 9% (time-dependent hazard ratio 21.5; 20.1–22.8). Prognosis after variceal bleeding has improved over time. In this large international cohort, up to 15% of UDCA-treated PBC patients developed major non-neoplastic, cirrhosis-associated hepatic complications within 15 years, but cumulative incidence has decreased over time. Biochemical non-response to UDCA and APRI were independent risk factors for these complications. Subsequent long-term outcome after complications is generally poor, but has improved over the past decades.

6 April 2018 in Hepatology
Verified
Journal Article
Closed access
PDF file
CPCarla F. Murillo Perez
Carla F. Murillo Perez
JGJorn C. Goet
Jorn C. Goet
WLWillem J. Lammers
Willem J. Lammers
AGAliya Gulamhusein
Aliya Gulamhusein
HBHenk R. van Buuren
Henk R. van Buuren
OGon behalf of the GLOBAL PBC Study Group
on behalf of the GLOBAL PBC Study Group